T3 Pharmaceuticals AG
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.t3pharma.com
First in Human Study of T3P-Y058-739 (T3P)
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Pembrolizumab+T3P-Y058-739Drug: T3P-Y058-739 (IV)Drug: T3P-Y058-739 (IT)
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- T3 Pharmaceuticals AG
- Target Recruit Count
- 100
- Registration Number
- NCT05120596
- Locations
- 🇪🇸
Vall d'Hebron Institute of Oncology, Barcelona, Spain
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
🇪🇸Institut Catala D'oncologia, L'Hospitalet De Llobregat, Spain
© Copyright 2025. All Rights Reserved by MedPath